KIRhub 2.0
Sign inResearch Use Only

ABL1

Sign in to save this workspace

UniProt P00519 · PDB · AlphaFold · Substrate: Abltide · Clone: full-length

Top inhibitors

#DrugInhibitionResidualKISSGini
1Ponatinib100.0%0.0%78.230.534
2Nintedanib99.9%0.1%90.230.608
3Bosutinib99.7%0.3%87.220.555
4Axitinib99.4%0.6%93.230.688
5Dasatinib98.6%1.4%87.970.699
6Nilotinib98.0%2.0%96.490.765
7Crizotinib97.0%3.0%91.390.581
8Tivozanib95.8%4.2%92.420.673
9Vandetanib95.7%4.3%95.740.723
10Repotrectinib93.6%6.4%84.210.608
11Pacritinib92.0%8.0%88.640.452
12Canertinib91.6%8.4%96.490.671
13Erdafitinib90.9%9.1%95.710.737
14Imatinib86.2%13.8%99.000.718
15Ripretinib82.9%17.1%92.950.674
16Brigatinib82.8%17.2%82.960.513
17Fedratinib82.7%17.3%96.210.576
18Dacomitinib80.8%19.2%97.990.664
19Pazopanib77.5%22.5%97.490.672
20Lenvatinib76.3%23.7%97.740.726

Paralog block

ABL1, ABL2_ARG

ABL1ABL2_ARG

EMT expression

  • Mesenchymal log2(TPM+1): 5.27
  • Epithelial log2(TPM+1): 4.37
  • Fold change: 0.90
  • Status: No significant change

Selectivity landscape vs inhibition on ABL1

Each point is one of the 92 approved drugs; color = inhibition % on ABL1.

Mutation lollipop

Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.

Variants (14)

ABL1 (E255K)
point
ABL1 (E255V)
point
ABL1 (F317I)
point
ABL1 (F317L)
point
ABL1 (G250E)
point
ABL1 (H396P)
point
ABL1 (M351T)
point
ABL1 (Q252H)
point
ABL1 (T315I)
point
ABL1 (V299L)
point
ABL1 (Y245F)
point
ABL1 (Y245F/Y412F)
compound
ABL1 (Y253F)
point
ABL1 (Y253H)
point

Mutation × cancer associations

MutationCancerOrganSource
E255Khaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
E255Klymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
E255Kcarcinoma_upper_aerodigestive_tractStomach/Digestive Tractref
E255Kcarcinoma_penisGenitourinary systemref
E255Vhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
E255Vlymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
F317Ihaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
F317Lhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
F317Llymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
G250Ehaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
G250Elymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
G250Ecarcinoma_lungLungref
H396Plymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
H396Phaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
M351Thaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
Q252Hhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
T315Ihaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
T315Ilymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
T315Imalignant_melanoma_skinSkinref
T315Iadnexal_tumour_skinSkinref
V299Lhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
V299Llymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
V299LLICA-CNLiverref
Y253Fhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
Y253Hhaematopoietic_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
Y253Hlymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
Y253Hcarcinoma_breastBreastref

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…